MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laduron, P. M.
Right arrow Articles by Leysen, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laduron, P. M.
Right arrow Articles by Leysen, J. E.

In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole

PM Laduron, PF Janssen, W Gommeren and JE Leysen

Binding characteristics of astemizole were studied in vitro in various receptor binding models and in vivo by determining the occupancy of histamine H1 receptors in guinea pig lung and cerebellum. In vitro, astemizole was found to have a high affinity for histamine H1 receptors, but great difficulties were encountered in proving this because of its high affinity for nonspecific binding sites. Since the equilibrium conditions were not reached in vitro, the real affinity of astemizole remains unclear and its receptor profile must be interpreted with caution. Nevertheless, the drug is certainly much more potent on histamine H1 receptors than on serotonin S2 and adrenergic alpha 1- receptors. Moreover, it was found to be devoid of antimuscarinic and antidopaminergic properties. The most striking property of this drug is its extremely slow dissociation rate from H1 receptors when assayed in vitro using [3H]-pyrilamine. Ex vivo experiments were performed in guinea pigs; astemizole was given orally to the animals, and the occupancy of H1 receptors in the lung and the cerebellum was determined in vitro by the [3H]-pyrilamine binding assay. Astemizole was found to occupy H1 receptors in lung at very low doses. Here again the most striking receptor binding property was its very long duration. The occupancy of H1 receptors in lung began to decline only 4-6 days after administration of the drug. However, there was a marked difference between the occupancy of peripheral and central receptors; indeed, in contrast to pyrilamine, astemizole at pharmacological doses did not reach the H1 receptors in the cerebellum, presumably because the drug does not readily cross the blood-brain barrier.

Volume 21, Issue 2, pp. 294-300, 03/01/1982
Copyright © 1982 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
S. J. Hill, C. R. Ganellin, H. Timmerman, J. C. Schwartz, N. P. Shankley, J. M. Young, W. Schunack, R. Levi, and H. L. Haas
International Union of Pharmacology. XIII. Classification of Histamine Receptors
Pharmacol. Rev., September 1, 1997; 49(3): 253 - 278.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Merlos, M. Giral, D. Balsa, R. Ferrando, M. Queralt, A. Puigdemont, J. García-Rafanell, and J. Forn
Rupatadine, a New Potent, Orally Active Dual Antagonist of Histamine and Platelet-Activating Factor (PAF)
J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 114 - 121.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1982 by the American Society for Pharmacology and Experimental Therapeutics